Anti-Aging & Peptide Therapy in Denver, CO
Restore Youthful Function
Physician-Supervised Peptide Therapy Based on Your Health, Goals, and the Available Clinical Evidence
Restore youthful function, optimize performance, and support your body's natural healing processes with personalized peptide therapy protocols.
Peptides are short chains of amino acids that can act as signaling molecules within the body. Different peptides interact with different biological pathways, which is why peptide-based medications have been studied and developed for a wide range of medical applications.
The term “peptide therapy,” however, encompasses therapies with very different levels of scientific evidence. Some peptide medications have FDA-approved indications and extensive human clinical research, while others remain investigational, have limited human data, or have primarily been studied in laboratory and animal models.
At R2 Medical Clinic, we believe patients should understand that distinction. Our approach is physician-supervised and individualized, with consideration given to the available human evidence, potential benefits, known and unknown risks, FDA status, laboratory findings, and each patient’s health and goals.
Many peptides used in peptide therapy have not been approved by the FDA for the indications in which they may be prescribed. Patients should consult with their healthcare provider to fully understand potential risks, benefits, and treatment options.
Why Are Peptides Studied?
Different peptides act on different biological pathways. Depending on the specific compound, researchers have investigated peptides for potential roles involving:
- Increased muscle growth and strength — accelerated lean mass development
- Faster recovery — reduced downtime from workouts, injuries, and physical stress
- Improved sleep quality — deeper, more restorative sleep cycles
- Enhanced energy and stamina — sustained vitality throughout the day
- Sharper cognition — improved mental clarity, focus, and memory
- Skin rejuvenation — increased collagen production and improved skin elasticity
- Fat loss support — enhanced metabolic function and fat metabolism
- Anti-aging effects — slowed cellular aging and improved overall vitality
- Immune support — strengthened immune system function
- Joint and tissue repair — accelerated healing of damaged tissues
These potential applications should not be interpreted as established benefits of every peptide. The quality of human evidence varies substantially by compound, and some peptides have little or no meaningful human clinical research.
Where fat loss is the primary goal, peptides are most often used as one component of a broader physician-supervised medical weight loss program — alongside lab work, body composition analysis, and ongoing monitoring — rather than on their own.
Peptide Informational Table
Select any peptide to view its dedicated page with mechanism, benefits, risks, FDA status, and supporting clinical evidence.
| Peptide | Primary Mechanism of Action (MOA) | FDA Approval | Human Clinical Evidence |
|---|---|---|---|
| Tesamorelin | GHRH analog that stimulates pituitary GH release → ↑ IGF-1 | Yes, there is an approved option. | Extensive – Multiple Phase III randomized trials |
| Ipamorelin | Selective ghrelin (GHS-R1a) receptor agonist → stimulates endogenous GH release | No | Limited – Early human pharmacodynamic studies and small clinical trials |
| Thymosin Beta-4 (TB4) | Actin-binding peptide that promotes cell migration, angiogenesis, and tissue repair | No | Limited – Primarily ophthalmology (dry eye/corneal healing); most data are preclinical |
| Sermorelin | GHRH (1-29) analog that stimulates physiologic GH secretion | Historical FDA approval; no currently marketed FDA-approved product | Extensive – Pediatric GH deficiency and adult endocrine studies |
| MK-677 (Ibutamoren) | Oral ghrelin receptor agonist that increases GH and IGF-1 secretion | No | Moderate – Multiple randomized clinical trials for aging, obesity, and GH deficiency |
| BPC-157 | Proposed modulation of nitric oxide signaling, angiogenesis, fibroblast migration, and tissue repair | No | Very Limited – Predominantly animal and laboratory studies |
| Thymosin Alpha-1 | Immunomodulator that enhances T-cell, dendritic cell, and innate immune function | Not FDA-approved (approved in several other countries) | Extensive – Hundreds of studies in hepatitis, sepsis, cancer, COVID-19, and immune disorders |
| GHK-Cu | Copper-binding tripeptide that stimulates collagen synthesis, tissue remodeling, and wound repair | No injectable FDA approval | Moderate – Human cosmetic/wound-healing studies; systemic use largely preclinical |
| MOTS-c | Mitochondrial-derived peptide that activates AMPK and improves metabolic signaling | No | Early – Small human metabolic studies; active clinical trials |
| SS-31 (Elamipretide) | Binds mitochondrial cardiolipin, improving ATP production and mitochondrial efficiency | Yes, there is an approved option. | Extensive – Multiple Phase I–III trials |
| Kisspeptin | Activates KISS1 receptor → stimulates GnRH → LH/FSH release | No | Moderate – Fertility, IVF, hypogonadism, and sexual function studies |
| Gonadorelin | Synthetic GnRH that stimulates LH and FSH secretion | Historical FDA approval for diagnostic/endocrine use; limited current commercial availability | Extensive – Decades of endocrine and fertility research |
| Oxytocin | Oxytocin receptor agonist causing uterine contraction, milk letdown, and central neuromodulation | Yes – Labor induction/augmentation and postpartum hemorrhage | Extensive – Thousands of clinical studies |
| Epithalon (Epitalon) | Proposed activation of telomerase, antioxidant pathways, and melatonin regulation | No | Limited – Mostly Russian/Eastern European studies; substantial preclinical evidence |
| AOD-9604 | hGH fragment (176–191) that promotes lipolysis and inhibits lipogenesis | No | Moderate – Several obesity trials; failed efficacy endpoints for approval |
| PT-141 (Bremelanotide) | Melanocortin MC4R/MC3R agonist that increases central sexual desire and arousal | Yes, there is an approved option. | Extensive – Phase III randomized trials |
| KPV | α-MSH-derived tripeptide that suppresses NF-κB and pro-inflammatory cytokines | No | Minimal – Primarily laboratory and animal research |
| NAD+ | Essential metabolic coenzyme involved in ATP production, mitochondrial function, DNA repair, and sirtuin activation | No (IV NAD+ is not FDA-approved as a drug) | Moderate – Numerous studies on NAD+ precursors; direct IV NAD+ evidence is limited |
- Mechanism of Action
- GHRH analog that stimulates pituitary GH release → ↑ IGF-1
- FDA Approval
- Yes, there is an approved option.
- Human Clinical Evidence
- Extensive – Multiple Phase III randomized trials
- Mechanism of Action
- Selective ghrelin (GHS-R1a) receptor agonist → stimulates endogenous GH release
- FDA Approval
- No
- Human Clinical Evidence
- Limited – Early human pharmacodynamic studies and small clinical trials
- Mechanism of Action
- Actin-binding peptide that promotes cell migration, angiogenesis, and tissue repair
- FDA Approval
- No
- Human Clinical Evidence
- Limited – Primarily ophthalmology (dry eye/corneal healing); most data are preclinical
- Mechanism of Action
- GHRH (1-29) analog that stimulates physiologic GH secretion
- FDA Approval
- Historical FDA approval; no currently marketed FDA-approved product
- Human Clinical Evidence
- Extensive – Pediatric GH deficiency and adult endocrine studies
- Mechanism of Action
- Oral ghrelin receptor agonist that increases GH and IGF-1 secretion
- FDA Approval
- No
- Human Clinical Evidence
- Moderate – Multiple randomized clinical trials for aging, obesity, and GH deficiency
- Mechanism of Action
- Proposed modulation of nitric oxide signaling, angiogenesis, fibroblast migration, and tissue repair
- FDA Approval
- No
- Human Clinical Evidence
- Very Limited – Predominantly animal and laboratory studies
- Mechanism of Action
- Immunomodulator that enhances T-cell, dendritic cell, and innate immune function
- FDA Approval
- Not FDA-approved (approved in several other countries)
- Human Clinical Evidence
- Extensive – Hundreds of studies in hepatitis, sepsis, cancer, COVID-19, and immune disorders
- Mechanism of Action
- Copper-binding tripeptide that stimulates collagen synthesis, tissue remodeling, and wound repair
- FDA Approval
- No injectable FDA approval
- Human Clinical Evidence
- Moderate – Human cosmetic/wound-healing studies; systemic use largely preclinical
- Mechanism of Action
- Mitochondrial-derived peptide that activates AMPK and improves metabolic signaling
- FDA Approval
- No
- Human Clinical Evidence
- Early – Small human metabolic studies; active clinical trials
- Mechanism of Action
- Binds mitochondrial cardiolipin, improving ATP production and mitochondrial efficiency
- FDA Approval
- Yes, there is an approved option.
- Human Clinical Evidence
- Extensive – Multiple Phase I–III trials
- Mechanism of Action
- Activates KISS1 receptor → stimulates GnRH → LH/FSH release
- FDA Approval
- No
- Human Clinical Evidence
- Moderate – Fertility, IVF, hypogonadism, and sexual function studies
- Mechanism of Action
- Synthetic GnRH that stimulates LH and FSH secretion
- FDA Approval
- Historical FDA approval for diagnostic/endocrine use; limited current commercial availability
- Human Clinical Evidence
- Extensive – Decades of endocrine and fertility research
- Mechanism of Action
- Oxytocin receptor agonist causing uterine contraction, milk letdown, and central neuromodulation
- FDA Approval
- Yes – Labor induction/augmentation and postpartum hemorrhage
- Human Clinical Evidence
- Extensive – Thousands of clinical studies
- Mechanism of Action
- Proposed activation of telomerase, antioxidant pathways, and melatonin regulation
- FDA Approval
- No
- Human Clinical Evidence
- Limited – Mostly Russian/Eastern European studies; substantial preclinical evidence
- Mechanism of Action
- hGH fragment (176–191) that promotes lipolysis and inhibits lipogenesis
- FDA Approval
- No
- Human Clinical Evidence
- Moderate – Several obesity trials; failed efficacy endpoints for approval
- Mechanism of Action
- Melanocortin MC4R/MC3R agonist that increases central sexual desire and arousal
- FDA Approval
- Yes, there is an approved option.
- Human Clinical Evidence
- Extensive – Phase III randomized trials
- Mechanism of Action
- α-MSH-derived tripeptide that suppresses NF-κB and pro-inflammatory cytokines
- FDA Approval
- No
- Human Clinical Evidence
- Minimal – Primarily laboratory and animal research
- Mechanism of Action
- Essential metabolic coenzyme involved in ATP production, mitochondrial function, DNA repair, and sirtuin activation
- FDA Approval
- No (IV NAD+ is not FDA-approved as a drug)
- Human Clinical Evidence
- Moderate – Numerous studies on NAD+ precursors; direct IV NAD+ evidence is limited
Human Evidence Key
| Rating | Interpretation |
|---|---|
| Extensive | Multiple randomized controlled trials and/or established clinical use |
| Moderate | Multiple human studies with encouraging evidence, but not standard therapy |
| Limited | Small clinical studies or early-phase trials |
| Very Limited / Minimal | Predominantly animal, laboratory, or mechanistic research with little human evidence |
Understanding FDA Approval and Peptide Research
Peptide therapies vary significantly in regulatory status and scientific evidence. Some peptide-based medications are FDA-approved for specific medical indications. Others are not FDA-approved, and some have limited or no high-quality human clinical research. FDA approval of a peptide for one indication does not mean it is approved for other uses.
When considering a therapy, we discuss what is known, what remains uncertain, potential risks, available alternatives, and the quality of evidence supporting its use.
How Peptide Therapy Works at R2 Medical
Peptide therapy at R2 Medical Clinic follows a structured, physician-guided process:
Step 1 — Comprehensive Assessment
Detailed health history, symptoms, goals, laboratory findings, and other relevant clinical information to determine whether peptide therapy is appropriate and, if so, which options may warrant consideration.
Step 2 — Custom Protocol Design
When therapy is clinically appropriate, your provider reviews the available options, quality of evidence, potential benefits, risks, alternatives, and limitations before developing an individualized treatment plan.
Step 3 — Ongoing Monitoring
Regular follow-up appointments and lab work to track your response, adjust dosing, and ensure safety and effectiveness over time.
FDA-Approved vs Investigational Peptides: What's the Difference?
Not all peptide therapies have the same regulatory status or the same level of scientific evidence. Some peptide-based medications have been reviewed and approved by the FDA for specific medical conditions, while others remain investigational or have limited human clinical research. Understanding these differences is an important part of making an informed treatment decision.
FDA-Approved Peptide Medications
An FDA-approved medication has undergone FDA review of data regarding its safety, effectiveness, manufacturing, and quality for a specific indication, dose, formulation, and patient population. FDA approval does not mean a medication is risk-free, but it does mean the FDA has determined that its benefits outweigh its known and potential risks for the approved use.
Some peptide-based medications have FDA-approved medical indications. However, an FDA-approved peptide used for another purpose may be considered off-label use.
What Does “Off-Label” Mean?
Off-label prescribing occurs when an FDA-approved medication is prescribed for a condition, dose, route of administration, or patient population that is different from its FDA-approved labeling. Healthcare providers generally may prescribe approved medications off-label when they determine that doing so is medically appropriate for an individual patient.
Importantly, FDA approval of a peptide for one condition does not mean the FDA has determined that it is safe or effective for every other proposed use.
What Is an Investigational Peptide?
An investigational peptide is one that is still being studied and has not received FDA approval for routine marketing for the proposed use. The amount of scientific evidence can vary considerably. Some investigational compounds have undergone human clinical trials, while others may have only limited human data or predominantly laboratory and animal research.
Early or preclinical research can be scientifically interesting, but it should not be interpreted as proof that a therapy is safe or effective in humans.
What About Compounded Peptides?
Compounded medications are another distinct category. Compounded drugs are not FDA-approved, even when they contain an active ingredient that is also found in an FDA-approved medication. The FDA does not review compounded products for safety, effectiveness, or quality before they are marketed. Compounded medications can serve an important medical need for certain patients, but they should not be represented as equivalent to an FDA-approved product.
Why This Distinction Matters
At R2 Medical Clinic, we believe patients should understand what is known—and what remains uncertain—before considering peptide therapy. The FDA status, quality of human evidence, potential benefits, known and unknown risks, alternatives, and individual health considerations should all be part of the treatment discussion.
FDA-approved does not mean appropriate for everyone, and investigational does not mean proven effective. The specific peptide, intended use, available evidence, and individual patient all matter.
Schedule Your Free Consultation
Medically reviewed by Erik Natkin, DO — Founder, R2 Medical Clinic. Content last reviewed July 2026.